On Friday, Zoetis Inc (NYSE:ZTS)’s shares declined -2.91% to $45.02.
Zoetis Inc.(ZTS) will take part in the 2015 Morgan Stanley Global Healthcare Conference on Friday, Sept. 18, in New York, N.Y. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. They are planned to present at 1:35 p.m. EDT.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms.
BorgWarner Inc. (NYSE:BWA)’s shares dropped -2.52% to $44.22.
Remy International, Inc. (REMY) declared recently that a special meeting of Remy stockholders has been planned in connection with BorgWarner Inc.’s (BWA) projected acquisition of Remy. The special meeting has been planned for Remy stockholders to, among other things, consider and vote upon a proposal to adopt the formerly declared merger agreement, dated as of July 12, 2015, reached among Remy, BorgWarner and a wholly owned partner of BorgWarner. Under the terms of the merger agreement, each share of common stock of Remy issued and outstanding right away preceding to the effective time of the merger (other than excluded shares and dissenting shares) will be converted into the right to receive $29.50 per share in cash, without interest and less any applicable withholding taxes.
The special meeting is presently planned to be held on Tuesday, September 22, 2015 at 10:00 a.m., local time, at Remy’s headquarters (600 Corporation Drive, Pendleton, Indiana 46064). Stockholders of record as of the close of business on August 14, 2015 will be entitled to notice of and to vote at (in person or by proxy) the special meeting and at any adjournment or postponement thereof.
BorgWarner Inc. manufactures and sells engineered automotive systems and components primarily for powertrain applications worldwide. The companys Engine segment offers turbochargers, timing devices and chain products, emissions systems, thermal systems, and diesel coldstart and gasoline ignition technology.
At the end of Friday’s trade, Anthera Pharmaceuticals Inc (NASDAQ:ANTH)‘s shares dipped -9.40% to $7.04.
Anthera Pharmaceuticals, Inc. (ANTH) declared financial results and an operational update for the second quarter ended June 30, 2015.
Net loss for the quarter and six months ended June 30, 2015 was $8.9 million and $16.6 million, respectively, contrast to $7.3 million and $15.2 million for the corresponding periods in 2014. The enhance in net loss both quarterly and year-to-date is mainly driven by higher clinical development expense for our blisibimod program and manufacturing and study preparation expenses for the Sollpura(TM) development program. The enhance in operating expense both quarterly and year-to-date is offset by revenues of $0.3 million and $0.5 million in connection with the amortization of license fee and FTE reimbursement from our collaborative partner, and $0.4 million and $0.9 million in cost share reimbursement from our partner. Furthermore, operating expense is reduced by $1.1 million in connection with our achievement of certain milestones specified in a research award granted to us by the Cystic Fibrosis Foundation Therapeutics (“CFFT”) for the development of Sollpura(TM). Comprised of in operating expense are $0.7 million and $1.2 million of non-cash stock-based compensation recorded for the three and six months ended June 30, 2015, contrast to $0.5 million and $1.3 million in the corresponding periods in 2014.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others.
TerraForm Power Inc (NASDAQ:TERP), ended its Friday’s trading session with -3.71% loss, and closed at $23.36.
SunEdison, Inc. (SUNE), the world’s largest renewable energy development company, and West Street Infrastructure Partners III (“WSIP”) and associates, recently declared the formation of a new $1 billion warehouse investment vehicle, the WSIP Warehouse, to fund construction costs and to acquire operating assets. TerraForm Power, Inc. (TERP), a global owner and operator of clean energy power plants, will have an exclusive call right over the warehoused assets.
The WSIP Warehouse is a $1 billion investment vehicle with $300 million equity committed, subject to certain conditions, by WSIP, the infrastructure fund managed by Goldman Sachs. The debt structuring will be led by Morgan Stanley, Bank of America and Deutsche Bank and will provide commitments for $700 million of debt in the form of a $500 million, five-year term loan and a $200 million, four-year revolving credit facility. SunEdison has the option to expand the facility by up to $1 billion to a total of $2 billion, subject to certain conditions.
TerraForm Power, Inc. owns and operates solar and wind generation assets serving utility, commercial, and residential customers. As of February 20, 2015, its portfolio compriseed of solar and wind projects located in the United States, Canada, the United Kingdom, and Chile with an aggregate nameplate capacity of 1,507.3 megawatt. The company was formerly known as SunEdison Yieldco, Inc. and changed its name to TerraForm Power, Inc. in May 2014. The company was founded in 2014 and is based in Bethesda, Maryland. TerraForm Power, Inc. is a partner of SunEdison, Inc.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
